Blocking EGFR signaling (using gefitinib) reduces active MAPK and inhibits proliferation of tamoxifen resistant breast cancer cells (Knowlden et al, 2003), while the MAPK inhibitor, U0126, partially restores tamoxifen sensitivity (Kurokawa et al, 2000). This evidence concerns the gene EGFR and breast cancer.